Liraglutide biobetter is under clinical development by BioLingus and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Liraglutide biobetter’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Liraglutide biobetter overview

liraglutide biobetter is under development for the treatment of type II diabetes and obesity. The drug candidate is administered sublingually, formulated as tablet. The drug candidate acts by targeting glucagon-like peptide 1 (GLP-1) receptor. It is developed based on oral peptide utility system (OPUS) platform technology.

BioLingus overview

BioLingus is a biotechnology company. It develops oral or sublingual delivery of peptides and proteins for chronic diseases and immune therapies. The company pipeline products include sublingual liraglutide, sublingual semaglutide, sublingual exenatide, sublingual insulin+, sublingual IL2, sublingual interferon-alfa and others. BioLingus OPUS technology platform offers oral administrative products for diabetes. The company’s project pipeline includes oral products with therapeutic applications in the area of diabetes type II, leishmaniasis and tuberculosis. BioLingus is headquartered in Hergiswil, Switzerland.

For a complete picture of Liraglutide biobetter’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.